CT Urogram & CT-Based Imaging in Reconstructive Urology
At a glance
CT urography answers an anatomic question. Choose phases around the suspected lesion and the decision the result will change. A full CTU is not required for every stone, stricture, episode of microscopic hematuria or postoperative follow-up.[1][2]
| Clinical question | Useful study | Limitation |
|---|---|---|
| High-risk microhematuria | Cystoscopy plus axial upper-tract imaging; usually CTU if suitable | CTU does not replace bladder inspection.[1] |
| Intermediate-risk microhematuria | Renal/bladder ultrasound with the guideline's cystoscopy pathway | Routine CTU adds exposure without being the default recommendation.[1] |
| Suspected stone | Ultrasound or noncontrast CT according to presentation | Contrast/excretory phases are added for a separate anatomic question, not automatically.[7] |
| Suspected ureteral injury or urinary leak | Contrast CT with appropriately delayed images in a stable patient | Poor excretion can limit localization; further delayed or direct studies may be needed.[5] |
| Suspected bladder rupture | Retrograde CT or conventional cystography | Excreted IV contrast passively filling the bladder is insufficient to exclude rupture.[5][6] |
| Differential renal function / drainage | Diuretic renography, usually MAG3 | Interpret function, drainage, hydration and bladder emptying together.[8] |
1. Indications and Alternatives
Hematuria and urothelial lesions
Apply the AUA/SUFU 2025 risk assessment, rather than a universal pre-urethroplasty CTU rule. Low/negligible-risk microhematuria generally begins with repeat urinalysis; intermediate-risk patients usually receive renal ultrasound and a cystoscopy discussion; high-risk patients receive cystoscopy and axial upper-tract imaging. When CTU is unsuitable, MR urography is an alternative; when both are unsuitable, retrograde pyelography with noncontrast imaging or ultrasound may be used. Gross hematuria requires a separate complete clinical evaluation.[1]
CTU may demonstrate filling defects, focal thickening or obstruction, but imaging alone does not establish histology. A suspected upper-tract lesion may require ureteroscopic assessment and tissue sampling. A negative scan does not exclude all urothelial disease.[10]
Ureteral reconstruction and congenital anatomy
Specify the operative question: narrowing location, opacified length, collecting-system duplication, relationship to a mass, or vascular anatomy. Thin sections and multiplanar reconstructions help map the upper tract. Poorly excreting or completely obstructed segments may remain unopacified, so a retrograde or antegrade study can supply additional luminal information.[2][5]
A crossing vessel on CT does not, by itself, prove the cause or functional severity of UPJ obstruction. Reconstructive selection also uses symptoms, serial anatomy and functional assessment. Neither a cortical-thickness measurement nor a delayed nephrogram is a substitute for a measured differential renal function.[8]
Fistula, collection and postoperative complication
Request an excretory phase when the question is a urinary leak and a retrograde cystogram when bladder integrity is the question. Communicate prior surgery, diversion anatomy, stents, drains, renal function and the suspected communication. Delayed contrast in a collection supports a urinary source; absent opacification does not reliably exclude a small leak in a poorly functioning unit.[5][6]
Complex pelvic fistulae may also need MRI, endoscopy or direct contrast studies. CT cannot certify flap viability, tissue vascularity or that an irradiated repair will succeed. See MRI and the fistula repair atlas.
2. CTU Protocol — Match the Acquisition to the Question
A CTU protocol is a radiology prescription, not a fixed three-phase requirement. The ESUR technical consensus describes selecting one, two or three phases according to indication and patient characteristics.[2]
| Acquisition | Main contribution | Planning point |
|---|---|---|
| Unenhanced | Stones, calcification and baseline lesion attenuation | Include when that information is needed; do not infer that split-bolus protocols cannot include an unenhanced scan.[2] |
| Nephrographic | Renal parenchyma and enhancement | Coordinate additional vascular or lesion-specific phases with radiology.[2] |
| Excretory | Contrast-filled collecting systems and ureters | Timing depends on excretion and the clinical question; incomplete opacification is not automatically a stricture.[2][3] |
| Split-bolus combined phase | Nephrographic and excretory information in fewer acquisitions | May reduce exposure, but additional delayed images can offset savings.[3] |
Dose is protocol-dependent. Do not present 3–5 mSv or 5–10 mSv as guaranteed doses. Scan length, patient size, scanner settings and repeat phases materially change exposure. In a single-center comparison of 241 CTU examinations, single-bolus imaging needed fewer repeat excretory phases and was faster, with a reported 25% higher dose than the compared split-bolus protocol. This is a protocol comparison, not a universal dose estimate.[3]
Provide prior studies to avoid duplicating acquisitions. Use the lowest exposure that still answers the diagnostic question; ultrasound or MRU may be preferable for repeated anatomic assessment in an appropriate patient.[2][7]
3. Iodinated Contrast
Renal risk and hydration
Distinguish contrast-associated AKI (temporal association) from contrast-induced AKI (causal attribution). The ACR–NKF consensus does not treat an eGFR below 30 as an absolute prohibition on a clinically necessary contrast CT.[4]
| Situation | Practical interpretation |
|---|---|
| Stable eGFR ≥30 mL/min/1.73 m² | Routine IV saline prophylaxis is not indicated for every patient. |
| eGFR 30–44 with recent AKI or other high-risk circumstances | Consider prophylaxis individually. |
| AKI or eGFR <30, not on maintenance dialysis | Discuss diagnostic benefit and alternatives; isotonic saline prophylaxis is indicated when not contraindicated by volume risk. |
| Maintenance dialysis | Do not initiate or reschedule dialysis solely to clear IV iodinated contrast; consider residual renal function and fluid burden. |
These recommendations concern intravenous contrast CT, not every intra-arterial exposure. Do not reduce contrast below a diagnostic dose merely to create a nominally “safer” but nondiagnostic study.[4]
Metformin and prior reactions
ACR 2026 does not require withholding metformin for IV contrast when there is no AKI and eGFR is ≥30. With AKI or severe CKD below 30, hold it at/before exposure and for 48 hours, then reassess renal function before restarting; specified arterial catheter procedures have additional considerations. FDA labeling/local policy may be more restrictive.[9]
Document the actual prior contrast reaction and agent. Shellfish or povidone-iodine allergy alone is not an iodinated-contrast allergy. For a prior same-class allergic-like reaction, coordinate agent selection, alternatives and any premedication with radiology; premedication does not eliminate breakthrough reactions or justify delaying an urgent diagnosis without considering the harm.[9]
Sequencing with MAG3
The cited SNMMI/EANM guideline does not establish a universal 48-hour wait after iodinated contrast or a mandatory CTU-first sequence. The prior OAT-competition explanation has been removed. Supply recent imaging, kidney-function changes and medication history to nuclear medicine; schedule according to the diagnostic question and the department's protocol. Acute renal deterioration after any event may affect interpretation.[8]
4. Trauma: CT, Cystography and Urethrography Have Different Roles
Resuscitation takes priority. CT is appropriate when the trauma patient's condition allows it; hemodynamic instability is not an instruction to delay definitive hemorrhage management for a CT scan.[5]
Pelvic fracture, hematoma or superior bladder displacement can raise concern for urethral injury, but none alone proves complete transection. Blood at the meatus after pelvic trauma is an indication for RUG. Repeated blind catheter attempts should be avoided; urinary drainage and any realignment decision depend on the injury and the treating trauma/urology team.[5]
For suspected bladder injury, actively fill retrograde by gravity with dilute water-soluble contrast using an appropriate cystography protocol. EAU describes 300–350 mL for adult trauma evaluation when tolerated; fresh repairs, small bladders and children need an individualized volume. Passive excretion from IV contrast cannot provide an adequate negative study. Conventional and CT cystography have comparable diagnostic performance when properly performed; CT also shows surrounding injuries.[6]
CT-RUG remains a specialized technique with a limited evidence base. It should not replace the established RUG/VCUG pathway for routine stricture planning. MRI can add information in selected posterior stenoses and complex periurethral disease.[11]
5. Retroperitoneal Fibrosis
CT or MRI can show periaortic/periureteral tissue and obstruction. Imaging distribution, clinical history and—when indicated—biopsy help distinguish idiopathic or IgG4-related disease from malignant and other secondary causes. FDG avidity is not a stand-alone diagnosis or an automatic steroid prescription. Medical therapy, drainage and ureterolysis are complementary options selected according to the cause and renal threat.[12]
Keep drug regimens and operative indications on their dedicated pages: ureterolysis and ureteral stricture.
6. Follow-up and Reporting
Do not impose a universal CTU at three months after urethroplasty or a fixed 4–6-week wait for a suspected leak. New fever, pain, renal deterioration or concerning drain output calls for timely clinical assessment and the study best suited to the suspected complication. Stable postoperative surveillance is procedure- and risk-specific; persistent dilatation alone does not prove failed reconstruction.[5][8]
A useful report identifies the indication, acquisitions and contrast, limitations of opacification, lesion/transition-point location, upstream findings, leaks/collections, stent/drain position and comparison with prior studies. Separate observed anatomy from inference about function or causation. If uncertainty will affect reconstruction, state which additional study could resolve it.[2][8]
References
1. AUA/SUFU. Microhematuria guideline, amended 2025. Guideline. 2025 amendment. Accessed September 11, 2026.
2. Van Der Molen AJ, Cowan NC, Mueller-Lisse UG, et al. CT urography: definition, indications and techniques. A guideline for clinical practice. Eur Radiol. 2008;18:4–17. doi:10.1007/s00330-007-0792-x. Expert technical consensus; PubMed.
3. Morrison N, Bryden S, Costa AF. Split vs. single bolus CT urography: comparison of scan time, image quality and radiation dose. Tomography. 2021. Full study.
4. Davenport MS, Perazella MA, Yee J, et al. Use of intravenous iodinated contrast media in patients with kidney disease: ACR–NKF consensus statements. Radiology. 2020;294:660–668. doi:10.1148/radiol.2019192094. Society PDF.
5. AUA. Urotrauma guideline, amended 2020. Guideline PDF. Accessed September 11, 2026.
6. EAU. Urological Trauma: bladder injury and diagnostic evaluation. 2026. Guideline. Accessed September 11, 2026.
7. EAU. Urolithiasis: diagnostic imaging. 2026. Guideline. Accessed September 11, 2026.
8. Taylor AT, Brandon DC, de Palma D, et al. SNMMI/EANM procedure standard for diuretic renal scintigraphy in adults with suspected upper urinary tract obstruction. Semin Nucl Med. 2018;48:377–390. doi:10.1053/j.semnuclmed.2018.02.010. Full guideline.
9. ACR. Manual on Contrast Media. 2026. Chapters on metformin and patient selection. Manual and updates. Accessed September 11, 2026.
10. EAU. Upper Urinary Tract Urothelial Cell Carcinoma: diagnosis. 2026. Guideline. Accessed September 11, 2026.
11. EAU. Urethral Strictures: diagnostic evaluation. 2026. Guideline. Accessed September 11, 2026.
12. Kermani TA, Crowson CS, Achenbach SJ, Luthra HS. Idiopathic retroperitoneal fibrosis: a retrospective review of clinical presentation, treatment, and outcomes. Mayo Clin Proc. 2011;86:297–303. Primary cohort.